do glp 1 agonists cause muscle loss The promise and peril of GLP-1 agonists: What we (and don't) know as of August 2024 Impact of Selected Glucagon-like Peptide-1

Description

[DOI] [PubMed] [Google Scholar] 61.Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials

For those whove struggled for years, they represent a powerful tool for finally gaining control and feeling a sense of progress that once seemed out of reach

10.2337/diabetes.50.3.609 191 WaughN.CumminsE.RoyleP.ClarC.MarienM.RichterB.et al (2010)

Moreover, combination therapies have demonstrated significant advantages, such as Novo Nordisks CagriSema (semaglutide + cagrilintide), which shows superior glycemic control and weight reduction effects compared to semaglutide alone, demonstrating that combination therapy can achieve more than the sum of its parts while reducing side effects

Additional Benefits: Reduced craving for food, decreased addictive behaviors, a significant reduction in major cardiac events (27% reduction in fatal heart attacks), 7% reduction in stroke, decreased occurrence of obesity-related cancers, improved fertility in both men and women, reduced heart failure rates, and increased survival in heart failure patients